Ha
Harmony Bio
San Francisco CAFounded 202030 employees
Private CapbiotechPrivateRare Disease
Platform: Hemophilia Gene
Market Cap
N/A
All Drugs
4
Clinical Trials
5
Failed / Terminated
1
FDA Approved
1
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Nidazumab | HAR-6921 | Phase 2 | 1 | CFTR | FabryIgAN | ||
| HAR-6503 | HAR-6503 | Approved | 2 | CDK2 | MigraineCKD | ||
| Tiratinib | HAR-6515 | Preclinical | 1 | FLT3 | Endometrial CaBCC | ||
| HAR-9296 | HAR-9296 | Phase 1 | 1 | CD19 | HNSCCCeliac |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (3)